Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.1% – Time to Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price dropped 8.1% on Tuesday . The stock traded as low as $43.98 and last traded at $43.5260. 751,091 shares changed hands during mid-day trading, a decline of 14% from the average daily volume of 872,345 shares. The stock had previously closed at $47.34.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research note on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $110.00 price objective on shares of Structure Therapeutics in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $110.91.

Structure Therapeutics Stock Up 2.1%

The company’s fifty day moving average is $50.19 and its two-hundred day moving average is $48.83. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -41.23 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC increased its position in Structure Therapeutics by 27.0% during the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after buying an additional 313,600 shares during the period. Handelsbanken Fonder AB acquired a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $1,041,000. SEB Asset Management AB purchased a new position in shares of Structure Therapeutics during the first quarter worth approximately $11,811,000. Principal Financial Group Inc. grew its position in shares of Structure Therapeutics by 36.6% during the first quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company’s stock worth $84,531,000 after acquiring an additional 469,554 shares during the last quarter. Finally, B Group Inc. purchased a new position in shares of Structure Therapeutics during the fourth quarter worth approximately $6,260,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.